Neurent Medical Raises €62.5M for Chronic Rhinitis Treatment

Galway, Ireland-based Neurent Medical has successfully closed an oversubscribed Series C funding round, bringing in a substantial €62.5 million (approximately $74 million). This significant capital infusion is earmarked to propel the commercial rollout of its innovative NEUROMARK® system, a minimally invasive treatment designed to address the root causes of chronic rhinitis.

The financing round was spearheaded by prominent medtech investor MVM Partners, with substantial backing from Sofinnova Partners. Demonstrating continued confidence in the company's trajectory, existing investors also participated, including EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, and Enterprise Ireland. The influx of capital underscores the growing recognition of Neurent Medical's potential to disrupt the management of a condition affecting millions globally.

Chronic rhinitis, a persistent inflammatory condition of the nasal passages, significantly impacts patient quality of life through symptoms like nasal congestion, runny nose, and sneezing. Neurent Medical's proprietary NEUROMARK® technology employs Impedance Controlled Radiofrequency to precisely target and modulate overactive posterior nasal nerves, offering a durable solution that moves beyond mere symptom management. This approach is gaining traction as a differentiated therapeutic option in the otolaryngology space.

Brian Shields, CEO of Neurent Medical, expressed enthusiasm for the new partnerships, stating, "We are delighted to welcome MVM Partners and Sofinnova Partners to the Neurent Medical team. This Series C financing will be instrumental in accelerating our commercial expansion and ensuring NEUROMARK reaches the patients and physicians who stand to benefit most." The company also announced the addition of Kyle Dempsey from MVM Partners and Cedric Moreau from Sofinnova Partners to its Board of Directors, bringing invaluable expertise in medtech investment and growth strategies.

Kyle Dempsey highlighted the significance of Neurent's technology, noting, "In this rapidly emerging category, Neurent has set a new standard with a best-in-class solution, powered by a proprietary impedance control system that delivers real-time feedback, giving clinicians greater treatment confidence, control, and predictability during every procedure." This technological edge is crucial in a market seeking predictable and effective interventions for chronic conditions.

The market for chronic rhinitis treatments is substantial, with unmet needs driving innovation. Neurent Medical's platform is well-positioned to capture a significant share by offering a minimally invasive procedure with a strong safety profile and durable results. The company's strategic focus includes not only expanding patient access to NEUROMARK® but also generating further clinical evidence across diverse patient populations and exploring pipeline advancements for additional indications, as noted by Cedric Moreau: "We also see significant potential to expand this platform into additional indications, and we are confident in our partnership with Neurent Medical at this pivotal stage of commercial growth."

With dual headquarters in Galway, Ireland, and U.S. operations in Braintree, Massachusetts, Neurent Medical is poised for significant growth. This funding round solidifies its position as a key player in the sinonasal disease treatment landscape, aiming to establish a new standard of care through its innovative radiofrequency technology.